预约演示
更新于：2025-12-31
Brivudine
溴夫定
更新于：2025-12-31
概要
基本信息
药物类型 小分子化药 |
别名 (E)-5-(2-Bromovinyl)-deoxyuridine、Brivudine (INN)、BVdU + [7] |
作用方式 抑制剂 |
作用机制 DNA-指导DNA聚合酶抑制剂、TYMS抑制剂(胸苷酸合成酶抑制剂) |
在研适应症 |
原研机构- |
最高研发阶段批准上市 |
首次获批日期 奥地利 (2002-03-05), |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C11H13BrN2O5 |
InChIKeyODZBBRURCPAEIQ-PIXDULNESA-N |
CAS号69304-47-8 |
关联
7
项与 溴夫定 相关的临床试验NCT07099157
Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster: A Multicenter, Randomized, Prospective Clinical Trial
CTR20211091
溴夫定片（125mg）在中国健康受试者中空腹/餐后给药条件下随机、开放、单剂量、四周期、两序列、完全重复交叉生物等效性试验
CTR20210797
溴夫定片在健康受试者空腹及餐后状态下，单中心、随机、开放、完全重复试验。
100 项与 溴夫定 相关的临床结果
登录后查看更多信息
100 项与 溴夫定 相关的转化医学
登录后查看更多信息
100 项与 溴夫定 相关的专利（医药）
登录后查看更多信息
497
项与 溴夫定 相关的文献（医药）2026-01-01INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Brivudine for treatment of varicella-zoster virus encephalitis
Article
作者: Tang, Shunli ; Guo, Feiying ; Shao, Zhaozhao
OBJECTIVES:
Varicella-zoster virus (VZV) encephalitis is a rare but severe complication of VZV. Intravenous acycloviris the standard treatment, with the potential side effect of renal impairment that can complicate the therapeutic course and pose an obstacle to recovery. The development of novel antiviral drugs and the optimization of clinical management become an urgent necessity.
METHODS AND RESULTS:
We describe the first case of VZV encephalitis with intolerance to intravenous acyclovir that was successfully treated with oral brivudine monotherapy without discernible sequelae.
CONCLUSION:
Brivudine is a promising therapy for VZV encephalitis, particularly in cases intolerant to traditional antivirals or complicated by renal impairment.
2025-09-01CLINICAL MICROBIOLOGY AND INFECTION
Herpes simplex virus and drug resistance—comprehensive update on resistance mutations and implications for clinical management: a narrative review
Review
作者: Dähne, Theo ; Nägele, Klaudia ; Leuzinger, Karoline ; Fuchs, Jonas ; Krumbholz, Andi ; Panning, Marcus ; Gosert, Rainer ; Jaki, Lena ; Pletz, Mathias W ; Khanna, Nina
BACKGROUND:
Antiviral drug resistance in herpes simplex virus 1 and 2 (HSV-1 and 2) is a significant clinical challenge, particularly in immunocompromised patients. Drug susceptibility testing (DST) aids clinical management and can be conducted through genotypic (partial genome sequencing) or phenotypic (cell culture) methods. Both have inherent limitations: genotypic DST is limited by outdated datasets lacking information on new helicase-primase inhibitors and corresponding phenotypic data as well as sparse clinical correlations. Phenotypic DST is mainly hampered by a lack of standardization and timely results.
OBJECTIVES:
This study aims to compile an up-to-date and comprehensive HSV drug resistance dataset encompassing all reported drug resistance-associated mutations (DRMs), polymorphisms, and viral phenotypes. This study also aims to aggregate clinical conditions with available DST data.
SOURCES:
A PubMed search identified studies (January 2016-September 2024) on DRMs associated with resistance to aciclovir, penciclovir, brivudine, foscarnet, cidofovir, amenamevir, and pritelivir. Data from a previous HSV resistance dataset (pre-2016) were also included.
CONTENT:
In this review, we summarize novel mutations in the thymidine kinase, polymerase, and helicase-primase genes of HSV conferring resistance to antiviral drugs. Clinical information was available for 513 mutations. In 90% of these (461 cases), viral phenotype and clinical assessment were congruent. However, 10% of cases not responding to antiviral therapy showed phenotypically susceptible virus isolates. We present a framework for clinical and diagnostic management of cases with drug-resistant HSV infection.
IMPLICATIONS:
This dataset paves the way to harmonize reporting of DRMs for diagnostic labs and to accelerate genotypic DST interpretation through aggregated data. Ongoing large-scale data collection of genotypic, phenotypic, and clinical data is crucial for evidence-based management of HSV antiviral resistance and clinical guidelines.
2025-01-02Expert Opinion On Drug Safety
Risk of drug-induced delirium in older patients- a pharmacovigilance study of FDA adverse event reporting system database
Article
作者: Li, Jiayu ; Zhou, Ying ; Jia, Boying ; Zhou, Shuang ; Wan, Liyan ; Cui, Yimin
BACKGROUND:
Drug-induced delirium is known risk factors associated with increased morbidity and mortality in older patients. The objective was to evaluate the risk of drug-related delirium in older patients based on the FDA Adverse Event Reporting System (FAERS).
RESEARCH DESIGN AND METHODS:
Delirium reports in older patients (age ≥65) extracted from the FAERS database using Open Vigil 2.1. The reported odds ratio and the proportional reported ratio were calculated to detect the adverse reaction signal of delirium. Combined with published evidence, suspected drugs were categorized as known, possible, or new potential delirium-risk-increasing drugs.
RESULTS:
Of the 130,885 reports (including 28,850 delirium events and 1,857 drugs) analyzed for this study, 314 positive signal drugs were detected. Positive signal drugs are mainly concentrated on the drug of nervous system, cardiovascular system , alimentary tract and metabolism and anti-infectives for systemic use. Of the positive signal drugs, 26.11% (82/314) were known delirium-risk increasing drugs, 44.90% (141/314) were possible and 28.98% (91/314) were new potential.
CONCLUSION:
Drug-induced delirium risk is prevalent in older patients, according to the FAERS. The risk level of drug-induced delirium should be taken into account to optimize drug therapy in clinical practice.
100 项与 溴夫定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 水痘带状疱疹病毒感染 | 奥地利 | 2002-03-05 | |
| 水痘带状疱疹病毒感染 | 比利时 | 2002-03-05 | |
| 水痘带状疱疹病毒感染 | 德国 | 2002-03-05 | |
| 水痘带状疱疹病毒感染 | 希腊 | 2002-03-05 | |
| 水痘带状疱疹病毒感染 | 意大利 | 2002-03-05 | |
| 水痘带状疱疹病毒感染 | 卢森堡 | 2002-03-05 | |
| 水痘带状疱疹病毒感染 | 葡萄牙 | 2002-03-05 | |
| 水痘带状疱疹病毒感染 | 西班牙 | 2002-03-05 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 胰腺癌 | 临床3期 | - | - | |
| 转移性胰腺腺癌 | 临床2期 | 美国 | 2007-09-01 | |
| 转移性胰腺腺癌 | 临床2期 | 阿根廷 | 2007-09-01 | |
| 转移性胰腺腺癌 | 临床2期 | 巴西 | 2007-09-01 | |
| 转移性胰腺腺癌 | 临床2期 | 智利 | 2007-09-01 | |
| 转移性胰腺腺癌 | 临床2期 | 法国 | 2007-09-01 | |
| 转移性胰腺腺癌 | 临床2期 | 德国 | 2007-09-01 | |
| 转移性胰腺腺癌 | 临床2期 | 匈牙利 | 2007-09-01 | |
| 转移性胰腺腺癌 | 临床2期 | 荷兰 | 2007-09-01 | |
| 转移性胰腺腺癌 | 临床2期 | 秘鲁 | 2007-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 13 | 醖獵製齋廠範製窪觸鏇(獵窪蓋網構鑰鏇糧鏇選) = 獵鑰齋構糧鑰鹽觸範醖 鹽遞齋鬱醖蓋艱齋鑰繭 (網襯壓構廠襯廠蓋鏇鑰 ) 更多 | - | 2006-06-20 | |||
临床2期 | 13 | 糧艱願鹽願鬱壓壓選鏇(淵壓鹹襯範淵廠壓壓窪) = 廠觸衊築鏇簾鏇糧顧膚 鬱製廠膚製艱選膚廠壓 (壓壓選糧簾繭壓網窪積 ) 更多 | 积极 | 2006-06-20 | |||
糧艱願鹽願鬱壓壓選鏇(淵壓鹹襯範淵廠壓壓窪) = 餘鏇鏇淵鹹鹽願衊鏇艱 鬱製廠膚製艱選膚廠壓 (壓壓選糧簾繭壓網窪積 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用